General Updates

September 16, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed to you that the Company has incorporated a wholly owned subsidiary company “Alivus Life Sciences Do Brasil Ltda.” in the State of Sao Paulo, Brazil on September 15, 2026. The relevant disclosure as prescribed under Regulation 30 of the SEBI LODR Regulations and SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure 1. Kindly take the above information on record. Thanking you Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri E(), Mumbai– 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Annexure 1 S.No. Particulars Remarks 1. Name of the target entity, details in brief Name: Alivus Life Sciences Do Brasil Ltda. such as size, turnover etc. Country of Incorporation: Brazil Authorized Capital: R$ 500,000.00 (five hundred thousand reais), divided into 500,000 (five hundred thousand shares) Turnover, Size: Not Applicable since it is a newly incorporated company. 2. Whether the acquisition would fall within This initial subscription does not fall within the related party transaction(s) and whether purview of Related Party Transaction. the promoter/ promoter group/ group companies have any interest in the entity The promoter / promoter group / group being acquired? If yes, nature of interest companies of the Company does not have any and details thereof and whether the interest in Alivus Life Sciences Do Brasil Ltda. same is done at “arms length” 3. Industry to which the entity being Pharmaceuticals acquired belongs 4. Objects and impact of acquisition Not applicable, as this is for incorporation of a (including but not limited to, disclosure wholly owned subsidiary of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) 5. Brief details of any governmental or Approved by Federative Republic of Brazil regulatory approvals required for the National Registrar of Legal Entities acquisition 6. Indicative time period for completion of Not Applicable the acquisition 7. Nature of consideration - whether cash Cash consideration or share swap and details of the same 8. Cost of acquisition or the price at which The Company shall subscribe to the share the shares are acquired capital of an amount not exceeding R$ 500,000.00 (five hundred thousand reais) (being 100% of the share capital). Percentage of shareholding / control 100% of the paid up share capital will be held by 9. acquired and / or number of shares the Company acquired 10. Brief background about the entity Date of Incorporation: September 15, 2026, acquired in terms of products/line of 18:50 (Brazil Time) business acquired, date of incorporation, history of last 3 years turnover, country Turnover: Not Applicable since it is a newly in which the acquired entity has presence incorporated company. and any other significant information (in brief) Country: Brazil